<DOC>
	<DOCNO>NCT00567320</DOCNO>
	<brief_summary>Cocaine addiction continue important public health problem US significant cost individual society . Among substance abuser , cocaine use recognize significant problem especially methadone-maintenance patient . In several study , rate cocaine use report range 30 60 percent methadone maintenance program ( Condelli et al . 1991 ; Hunt et al . 1984 ; Kidorf Stitzer 1993 ; Kosten et al . 1988 ) . In patient , cocaine use seem predictor poor clinical outcome ( Hartel et al . 1995 ; Kosten et al . 1987a ) . The development effective pharmacotherapies cocaine use disorder , especially opioid-dependent population great importance . Unfortunately , effective pharmacotherapies exist . 1 . To determine safety tolerability varenicline cocaine-using methadone-stabilized subject . 2 . To determine varenicline efficacious reduce cocaine-use methadone-stabilized subject .</brief_summary>
	<brief_title>Efficacy Varenicline Methadone-Stabilized Cocaine Users</brief_title>
	<detailed_description>For pilot study , hope recruit total 40 subject , 20 subject varenicline group , 20 placebo-control group . Assuming significant finding , data enable u estimate possible effect size carrying-out large study . For preliminary analysis prelude planning large controlled study , clinically require effect size 20 % difference rate cocaine positive urine self-reported cocaine use active medication placebo group . We adjust multiple comparison placebo group since pilot study , use two-tailed significance level 0.05 employ repeat measure analysis variance ( ANOVA ) Hierarchical Linear Modeling ( HLM , see ) statistical analysis 16-week study period . An Amendment make new Updated consent form include new FDA finding study medication Varenicline . '' Varenicline may also cause change behavior , agitation , depress mood , suicidal ideation suicidal behavior . '' Currently 30 subject complete study . This study suspend due new concern , Department Veterans Affairs P.I . James Poling agree . Study publish . ( April 2011 )</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Males females 18 55 year old eligible study . Females must pregnant determined pregnancy screening , breast feeding , must use acceptable birth control method study participation . Current opioid dependence evidence documentation prior treatment opioid dependence sign withdrawal , selfreported history opioid dependence consecutive 12 month period positive urine opiate . Subjects must fulfill Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criteria opioid dependence . Subjects must history cocaine use , report street cocaine use minimum 1/2 gram precede 30 day . Subjects must meet DSMIV criterion cocaine dependence abuse , laboratory confirmation recent cocaine use ( positive urine cocaine ) month prior study entry . Subjects must treatmentseekers opioid cocaine use . Subjects must smoke least 10 cigarette per day least one year . Varenicline 's safety study smoker . History heart disease , leave ventricular hypertrophy , ischemic ECG change , chest pain , arrhythmia , hypertension . History severe renal hepatic disease . History psychosis , schizophrenia , bipolar major depressive disorder . History seizure disorder . Current diagnosis alcohol , benzodiazepine drug abuse dependence ( opiate , cocaine , nicotine ) . Current use overthecounter prescription psychoactive drug ( antidepressant , anxiolytic , antipsychotic , mood stabilizer , psychostimulants ) . Liver function test ( ALT AST ) great 3 time normal . Known allergy varenicline methadone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>varenicline</keyword>
</DOC>